lonafarnib has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, S; Pillaiyar, T | 1 |
| Bachmann, HS; Baiker, A; Ehrhardt, A; Hoyos, M; Mautner, L; Weber, L | 1 |
1 review(s) available for lonafarnib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |
1 other study(ies) available for lonafarnib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Effect of farnesyltransferase inhibitors on SARS-CoV-2.
Topics: COVID-19; Enzyme Inhibitors; Farnesyltranstransferase; Humans; SARS-CoV-2 | 2023 |